Gross Profit Analysis: Comparing Bausch Health Companies Inc. and Vericel Corporation

Bausch vs. Vericel: A Decade of Gross Profit Trends

__timestampBausch Health Companies Inc.Vericel Corporation
Wednesday, January 1, 2014600890000011503000
Thursday, January 1, 2015785380000024698000
Friday, January 1, 2016706300000026076000
Sunday, January 1, 2017617600000033570000
Monday, January 1, 2018602900000058697000
Tuesday, January 1, 2019625100000080279000
Wednesday, January 1, 2020577800000084228000
Friday, January 1, 20216040000000106025000
Saturday, January 1, 20225760000000109788000
Sunday, January 1, 20236198000000135576000
Loading chart...

Cracking the code

Gross Profit Trends: Bausch Health vs. Vericel Corporation

In the ever-evolving landscape of the healthcare industry, understanding financial performance is crucial. This analysis delves into the gross profit trends of Bausch Health Companies Inc. and Vericel Corporation from 2014 to 2023. Bausch Health, a major player, consistently outperformed Vericel, with gross profits peaking in 2015 at approximately $7.85 billion. Despite fluctuations, Bausch Health maintained a robust average gross profit of around $6.32 billion annually. In contrast, Vericel, a smaller entity, demonstrated impressive growth, with gross profits increasing over tenfold from 2014 to 2023, reaching about $135.6 million. This growth trajectory highlights Vericel's expanding market presence. The data underscores the contrasting scales and growth dynamics of these companies, offering valuable insights for investors and industry analysts alike.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025